Comment on "Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics".
作者信息
Behdarvand Dehkordi Fereshteh, Chehelgerdi Mohammad
机构信息
Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran.
Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
出版信息
Clin Proteomics. 2023 Oct 25;20(1):46. doi: 10.1186/s12014-023-09433-w.
Abstract
摘要
相似文献
1
Comment on "Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics".对《脑脊液中camk2a基线水平预测多发性硬化症的长期进展。临床蛋白质组学》的评论
Clin Proteomics. 2023 Oct 25;20(1):46. doi: 10.1186/s12014-023-09433-w.
2
Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis.基线时脑脊液中钙/钙调蛋白依赖性蛋白激酶2A（CaMK2A）水平可预测多发性硬化症的长期进展。
Clin Proteomics. 2023 Aug 29;20(1):33. doi: 10.1186/s12014-023-09418-9.
3
In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study.寻找多发性硬化症疲劳的脑脊液生物标志物：一项蛋白质组学研究。
J Sleep Res. 2019 Jun;28(3):e12721. doi: 10.1111/jsr.12721. Epub 2018 Jul 1.
4
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.脑脊液几丁质酶 3 样蛋白 1 水平与多发性硬化症的转化相关。
Brain. 2010 Apr;133(Pt 4):1082-93. doi: 10.1093/brain/awq035. Epub 2010 Mar 17.
5
Cerebrospinal fluid proteomics in multiple sclerosis.多发性硬化症中的脑脊液蛋白质组学
Biochim Biophys Acta. 2015 Jul;1854(7):746-56. doi: 10.1016/j.bbapap.2014.12.013. Epub 2014 Dec 16.
6
A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases.一种用于检测神经系统疾病中脑脊液反应性的新型非偏 proteomic 方法。
Mol Cell Proteomics. 2011 Jun;10(6):M110.000042. doi: 10.1074/mcp.M110.000042. Epub 2011 Mar 18.
7
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.综合生物化学、蛋白质组学和代谢组学脑脊液生物标志物可预测多发性硬化症的临床转化。
Brain Commun. 2021 Apr 19;3(2):fcab084. doi: 10.1093/braincomms/fcab084. eCollection 2021.
8
Proteomics-based technologies in the discovery of biomarkers for multiple sclerosis in the cerebrospinal fluid.基于蛋白质组学的技术在脑脊液中多发性硬化症生物标志物的发现。
Curr Mol Med. 2011 Jun;11(4):326-49. doi: 10.2174/156652411795677981.
9
Discovery of Biomarkers for Amyotrophic Lateral Sclerosis from Human Cerebrospinal Fluid Using Mass-Spectrometry-Based Proteomics.基于质谱蛋白质组学从人脑脊液中发现肌萎缩侧索硬化症的生物标志物
Biomedicines. 2023 Apr 23;11(5):1250. doi: 10.3390/biomedicines11051250.
10
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.几丁质酶 3 样蛋白 1：临床孤立综合征的预后生物标志物。
Brain. 2015 Apr;138(Pt 4):918-31. doi: 10.1093/brain/awv017. Epub 2015 Feb 13.
本文引用的文献
1
Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis.基线时脑脊液中钙/钙调蛋白依赖性蛋白激酶2A（CaMK2A）水平可预测多发性硬化症的长期进展。
Clin Proteomics. 2023 Aug 29;20(1):33. doi: 10.1186/s12014-023-09418-9.
2
Polypharmacy and multiple sclerosis: A population-based study.药物滥用与多发性硬化症：基于人群的研究。
Mult Scler. 2023 Jan;29(1):107-118. doi: 10.1177/13524585221122207. Epub 2022 Oct 27.
3
A Brief Overview on BDNF-Trk Pathway in the Nervous System: A Potential Biomarker or Possible Target in Treatment of Multiple Sclerosis?神经系统中脑源性神经营养因子-酪氨酸激酶受体通路概述：多发性硬化症治疗中的潜在生物标志物或可能靶点？
Front Neurol. 2022 Jul 12;13:917527. doi: 10.3389/fneur.2022.917527. eCollection 2022.
4
Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain.体内细胞类型特异性生物素标记可解析小鼠大脑中区域神经元和星形胶质细胞蛋白质组的差异。
Nat Commun. 2022 May 25;13(1):2927. doi: 10.1038/s41467-022-30623-x.
Zotero 插件